Second-generation antipsychotic agents (SGAs) cause serious metabolic side effects, including weight gain, dyslipidemia, and glucose metabolism abnormalities, which occur by unknown mechanisms. Therefore, the search for prospective markers for antipsychotic-induced weight gain (AIWG) has been of major interest. So far, predictive factors predisposing patients to the develop obesity and related metabolic disturbances induced by SGAs have been relatively less studied among large samples of Chinese schizophrenic patients. In this study, 264 Han Chinese inpatients diagnosed with schizophrenia or schizoaffective disorder initiated treatment with olanzapine (n=131) or risperidone (n=133) and were followed for 12weeks. Anthropometric measurements and laboratory analyses of thyroid hormone, fasting plasma glucose (FPG), and lipid levels were conducted as part of routine medical care. The results showed baseline thyroxine (T4) and waist:hip ratio (WHR)were negatively correlated to AIWG (T4: rs=-0.154, P=0.014; WHR: rs=-0.199, P=0.008). Correlations remained significant after multiple regression analyses. The two treatment groups statistically differed for changes in body mass index, WHR, LDL cholesterol, and FPG; in both groups FPG decreased at first and then increased. Our findings suggest basal T4 and WHR may serve as early biomarkers for weight gain as a side effect of single-SGA treatment.
Keywords: Schizophrenia; Second-generation antipsychotic agents; Thyroid hormone; Waist:hip ratio.
Copyright © 2017 Elsevier Ltd. All rights reserved.